RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RAPP?
Source: moomoo
Company Performance: The therapeutics company reported a 5% increase in shares, indicating positive market response.
Grant Approval: The company has received grants in China aimed at supporting the development of epilepsy drugs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.540
Low
40.00
Averages
54.60
High
80.00
Current: 30.540
Low
40.00
Averages
54.60
High
80.00
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Company Performance: The therapeutics company reported a 5% increase in shares, indicating positive market response.
Grant Approval: The company has received grants in China aimed at supporting the development of epilepsy drugs.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
Rapport Partners with Tenacia for RAP-219 Development in Greater China
- Partnership Highlights: Rapport Therapeutics has partnered with Tenacia Biotechnology, granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, covering indications such as epilepsy and bipolar disorder, which is expected to accelerate the global development of the drug.
- Financial Gains: Under the agreement, Rapport will receive an upfront payment of $20 million and has the potential to earn up to $308 million in development and commercialization milestone payments, along with tiered royalties, significantly enhancing the company's financial position.
- Clinical Trial Plans: RAP-219 demonstrated significant efficacy in a Phase 2 trial for drug-resistant epilepsy, with a Phase 3 trial expected to initiate in Q2 2026, further validating its potential in epilepsy treatment.
- Market Demand: Tenacia's regional expertise will expand the global reach of RAP-219, addressing the urgent need for innovative treatments for epilepsy and bipolar disorder in Greater China, facilitating faster patient access to this potential best-in-class therapy.
See More
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials
- FDA Approval: Rapport Therapeutics has received FDA clearance to advance RAP-219 into registrational trials, with plans to initiate its Phase 3 program in focal onset seizures in Q2 2026, marking a significant advancement in the epilepsy treatment landscape.
- Clinical Data Support: The robust Phase 2a data positions RAP-219 as a potential best-in-class therapy, aimed at addressing the limitations of current treatments in tolerability and efficacy, thereby fulfilling a critical unmet need for patients.
- Multicenter Trial Design: The Phase 3 trial will be a multicenter, randomized, double-blind study enrolling adults, focusing on seizure frequency reduction and long-term safety, which is expected to lay the groundwork for future market introduction.
- Sufficient Funding: As of the third quarter, Rapport reported $531 million in cash and short-term investments, providing ample resources to fund operations into the second half of 2029, ensuring ongoing investment in R&D and market expansion.
See More
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million
- Share Increase: Cormorant Asset Management disclosed a purchase of 251,600 additional shares of Rapport Therapeutics in its SEC filing on November 14, 2025, bringing its total holdings to 3,192,521 shares valued at approximately $94.82 million, indicating a bullish outlook on the biotech firm.
- Asset Management Scale: This increase positions Rapport as 6.54% of Cormorant's 13F assets under management, reflecting the firm's investment strategy in the biopharmaceutical sector and confidence in future growth prospects.
- Market Performance: As of November 14, 2025, Rapport Therapeutics shares were priced at $24.37, up 10.87% over the past year, although slightly underperforming the S&P 500, highlighting market interest in its potential drug candidates.
- Financial Status: Despite reporting a net loss of $26.9 million in Q3, Rapport holds $513 million in cash and short-term investments, expected to sustain operations into the second half of 2029, indicating ongoing commitment to research and development.
See More
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Company Performance: The therapeutics company reported a 5% increase in shares, indicating positive market response.
Grant Approval: The company has received grants in China aimed at supporting the development of epilepsy drugs.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
Rapport Partners with Tenacia for RAP-219 Development in Greater China
- Partnership Highlights: Rapport Therapeutics has partnered with Tenacia Biotechnology, granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, covering indications such as epilepsy and bipolar disorder, which is expected to accelerate the global development of the drug.
- Financial Gains: Under the agreement, Rapport will receive an upfront payment of $20 million and has the potential to earn up to $308 million in development and commercialization milestone payments, along with tiered royalties, significantly enhancing the company's financial position.
- Clinical Trial Plans: RAP-219 demonstrated significant efficacy in a Phase 2 trial for drug-resistant epilepsy, with a Phase 3 trial expected to initiate in Q2 2026, further validating its potential in epilepsy treatment.
- Market Demand: Tenacia's regional expertise will expand the global reach of RAP-219, addressing the urgent need for innovative treatments for epilepsy and bipolar disorder in Greater China, facilitating faster patient access to this potential best-in-class therapy.
See More
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials
- FDA Approval: Rapport Therapeutics has received FDA clearance to advance RAP-219 into registrational trials, with plans to initiate its Phase 3 program in focal onset seizures in Q2 2026, marking a significant advancement in the epilepsy treatment landscape.
- Clinical Data Support: The robust Phase 2a data positions RAP-219 as a potential best-in-class therapy, aimed at addressing the limitations of current treatments in tolerability and efficacy, thereby fulfilling a critical unmet need for patients.
- Multicenter Trial Design: The Phase 3 trial will be a multicenter, randomized, double-blind study enrolling adults, focusing on seizure frequency reduction and long-term safety, which is expected to lay the groundwork for future market introduction.
- Sufficient Funding: As of the third quarter, Rapport reported $531 million in cash and short-term investments, providing ample resources to fund operations into the second half of 2029, ensuring ongoing investment in R&D and market expansion.
See More
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million
- Share Increase: Cormorant Asset Management disclosed a purchase of 251,600 additional shares of Rapport Therapeutics in its SEC filing on November 14, 2025, bringing its total holdings to 3,192,521 shares valued at approximately $94.82 million, indicating a bullish outlook on the biotech firm.
- Asset Management Scale: This increase positions Rapport as 6.54% of Cormorant's 13F assets under management, reflecting the firm's investment strategy in the biopharmaceutical sector and confidence in future growth prospects.
- Market Performance: As of November 14, 2025, Rapport Therapeutics shares were priced at $24.37, up 10.87% over the past year, although slightly underperforming the S&P 500, highlighting market interest in its potential drug candidates.
- Financial Status: Despite reporting a net loss of $26.9 million in Q3, Rapport holds $513 million in cash and short-term investments, expected to sustain operations into the second half of 2029, indicating ongoing commitment to research and development.
See More
